Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Temsirolimus

FDA-approved product (solution, intravenous), marketed as Temsirolimus, Torisel.

Registered studies
50+
Lab records
0
Pathogens at ≥40%
4 of 4

Chemical structure

Chemical structure of Temsirolimus
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • Cancer
  • Clear cell renal carcinoma
  • Mantle cell lymphoma
  • Neoplasm
  • Renal cell carcinoma

Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗

WHO therapeutic group
Mammalian target of rapamycin (mtor) kinase inhibitors
Anti-infective classification
Not classified as an anti-infective.

Repurposing investigation

This medicine is being investigated here for AI-predicted antimicrobial activity against MRSA, E. coli, K. pneumoniae and M. tuberculosis. It was surfaced computationally for further investigation; it is not an established treatment for these infections.

AI-predicted activity

AI prediction · nothing measured
  • MRSA70.1% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • E. coli59.0% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • K. pneumoniae46.1% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • M. tuberculosis60.4% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

50+registered studies name this medicine, for any condition. The registry search keeps the first 50, so there may be more. See them below.

Experimental

No evidence found

No laboratory measurement against the four pathogens in the ChEMBL records loaded here.

Open Temsirolimus in ChEMBL Registered studies below

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

Not yet docked: queued in the docking rundetails

KPC-2 carbapenemase ↗ (K. pneumoniae)

Not yet docked: queued in the docking rundetails

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

Not yet docked: queued in the docking rundetails

Dihydrofolate reductase ↗ (MRSA)

Not yet docked: queued in the docking rundetails

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Temsirolimus with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • Everolimus for Treatment of Disfiguring Cutaneous Lesions in Neurofibromatosis1 CRAD001CUS232T

    NCT02332902 · start 2015-02

    Registered record
    Registry ID
    NCT02332902
    Conditions
    Neurofibromatosis 1
    Interventions
    Everolimus
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2015-02
    Completion
    2016-03
    Enrolment
    24

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionNeurofibromatosis 1
    InterventionEverolimus
    PhasePhase 2
    Registry statusCompleted

  • Prospective Evaluation of the Efficacy of Sirolimus (Rapamune®) in the Treatment of Severe Arteriovenous Malformations

    NCT02042326 · start 2014-09-12

    Registered record
    Registry ID
    NCT02042326
    Conditions
    Arteriovenous Malformations
    Interventions
    Sirolimus
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Recruiting
    Start
    2014-09-12
    Completion
    2027-09
    Enrolment
    50

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionArteriovenous Malformations
    InterventionSirolimus
    PhasePhase 2
    Registry statusRecruiting

  • Evaluation of New Specifications (2.25mm) of FirehawkTM in the Treatment of Coronary Heart Disease ( Firehawk_2.25 )

    NCT02688868 · start 2014-05

    Registered record
    Registry ID
    NCT02688868
    Conditions
    Coronary Heart Disease
    Interventions
    FirehawkTM 2.25mm
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Completed
    Start
    2014-05
    Completion
    2020-12
    Enrolment
    38

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionCoronary Heart Disease
    InterventionFirehawkTM 2.25mm
    PhaseNot applicable
    Registry statusCompleted

  • Differentiating Everolimus Versus Sirolimus in Combination With Calcineurin Inhibitors in Kidney Transplant Patients

    NCT02062892 · start 2013-12

    Registered record
    Registry ID
    NCT02062892
    Conditions
    Kidney Transplantation
    Interventions
    Everolimus; Sirolimus
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Withdrawn
    Start
    2013-12
    Completion
    2014-06
    Enrolment
    0

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionKidney Transplantation
    InterventionEverolimus; Sirolimus
    PhasePhase 4
    Registry statusWithdrawn

  • RAD001 in Patients With Chronic Phase Chronic Myeloid Leukemia w/ Molecular Disease.

    NCT01188889 · start 2013-09

    Registered record
    Registry ID
    NCT01188889
    Conditions
    Chronic Myeloid Leukemia
    Interventions
    RAD001; Imatinib
    Study type
    INTERVENTIONAL
    Phase
    Phase 1 / Phase 2
    Registry status
    Withdrawn
    Start
    2013-09
    Completion
    2017-12
    Enrolment
    0

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionChronic Myeloid Leukemia
    InterventionRAD001; Imatinib
    PhasePhase 1 / Phase 2
    Registry statusWithdrawn

  • A Pilot Study Comparing the Safety and Efficacy of Everolimus With Other Medicines in Recipients of ECD/DCD Kidneys

    NCT01878786 · start 2013-06

    Registered record
    Registry ID
    NCT01878786
    Conditions
    Delayed Graft Function
    Interventions
    Everolimus; Tacrolimus; Mycophenolate mofetil (MMF/MPA)
    Study type
    INTERVENTIONAL
    Phase
    Phase 2 / Phase 3
    Registry status
    Terminated
    Start
    2013-06
    Completion
    2017-12
    Enrolment
    25

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionDelayed Graft Function
    InterventionEverolimus; Tacrolimus; Mycophenolate mofetil (MMF/MPA)
    PhasePhase 2 / Phase 3
    Registry statusTerminated

  • Topical Rapamycin to Erase Angiofibromas in TSC

    NCT01526356 · start 2012-05

    Registered record
    Registry ID
    NCT01526356
    Conditions
    Angiofibromas; Tuberous Sclerosis
    Interventions
    Placebo; Rapamycin; Rapamycin
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2012-05
    Completion
    2014-08
    Enrolment
    179

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAngiofibromas; Tuberous Sclerosis
    InterventionPlacebo; Rapamycin; Rapamycin
    PhasePhase 2
    Registry statusCompleted

  • Minitransplants With HLA-matched Donors : Comparison Between 2 GVHD Prophylaxis Regimens

    NCT01428973 · start 2011-09

    Registered record
    Registry ID
    NCT01428973
    Conditions
    Graft-Versus-Host Disease; Hematological Malignancies
    Interventions
    Mycophenolate mofetil; Sirolimus
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Unknown
    Start
    2011-09
    Completion
    2024-12
    Enrolment
    200

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionGraft-Versus-Host Disease; Hematological Malignancies
    InterventionMycophenolate mofetil; Sirolimus
    PhasePhase 2
    Registry statusUnknown

  • Ixabepilone and Temsirolimus in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery

    NCT01375829 · start 2011-06-27

    Registered record
    Registry ID
    NCT01375829
    Conditions
    Adult Solid Neoplasm
    Interventions
    Ixabepilone; Pharmacological Study; Temsirolimus
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Active not recruiting
    Start
    2011-06-27
    Completion
    2027-03-19
    Enrolment
    22

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAdult Solid Neoplasm
    InterventionIxabepilone; Pharmacological Study; Temsirolimus
    PhasePhase 1
    Registry statusActive not recruiting

  • Everolimus, Erlotinib Hydrochloride, and Radiation Therapy in Treating Patients With Recurrent Head and Neck Cancer Previously Treated With Radiation Therapy

    NCT01332279 · start 2011-04

    Registered record
    Registry ID
    NCT01332279
    Conditions
    Recurrent Metastatic Squamous Neck Cancer With Occult Primary; Recurrent Salivary Gland Cancer; Recurrent Squamous Cell Carcinoma of the Hypopharynx; Recurrent Squamous Cell Carcinoma of the Larynx; Recurrent Squamous Cell Carcinoma of the Lip and Oral Cavity; Recurrent Squamous Cell Carcinoma of the Oropharynx; Recurrent Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity; Recurrent Verrucous Carcinoma of the Larynx; Recurrent Verrucous Carcinoma of the Oral Cavity; Salivary Gland Squamous Cell Carcinoma; Tongue Cancer
    Interventions
    everolimus; erlotinib hydrochloride; biopsy; laboratory biomarker analysis; immunohistochemistry staining method; polyacrylamide gel electrophoresis; pharmacological study; external beam radiation therapy; microarray analysis
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Withdrawn
    Start
    2011-04
    Completion
    2011-05
    Enrolment
    0

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionRecurrent Metastatic Squamous Neck Cancer With Occult Primary; Recurrent Salivary Gland Cancer; Recurrent Squamous Cell Carcinoma of the Hypopharynx; Recurrent Squamous Cell Carcinoma of the Larynx +7 more
    Interventioneverolimus; erlotinib hydrochloride; biopsy; laboratory biomarker analysis +5 more
    PhasePhase 1
    Registry statusWithdrawn

  • Restenosis Treatment With Rapamycin Eluting Stent or Paclitaxel Eluting Balloon Catheter (RESTENOZA)

    NCT01255956 · start 2010-12

    Registered record
    Registry ID
    NCT01255956
    Conditions
    In-Stent Restenosis
    Interventions
    Rapamycin eluting stent implantation; Paclitaxel eluting balloon catheter
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Unknown
    Start
    2010-12
    Completion
    2012-07
    Enrolment
    200

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionIn-Stent Restenosis
    InterventionRapamycin eluting stent implantation; Paclitaxel eluting balloon catheter
    PhasePhase 3
    Registry statusUnknown

  • Efficacy and Safety of Bevacizumab/Temsirolimus Combination to Treat Advanced Renal Cell Carcinoma

    NCT01264341 · start 2010-12

    Registered record
    Registry ID
    NCT01264341
    Conditions
    Kidney Cancer
    Interventions
    Bevacizumab; Temsirolimus
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Terminated
    Start
    2010-12
    Completion
    2015-07
    Enrolment
    39

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionKidney Cancer
    InterventionBevacizumab; Temsirolimus
    PhasePhase 2
    Registry statusTerminated

  • Graft-Versus-Host Disease Prophylaxis in Treating Patients With Hematologic Malignancies Undergoing Unrelated Donor Peripheral Blood Stem Cell Transplant

    NCT01231412 · start 2010-11

    Registered record
    Registry ID
    NCT01231412
    Conditions
    Acute Lymphoblastic Leukemia; Acute Myeloid Leukemia; Aggressive Non-Hodgkin Lymphoma; Chronic Lymphocytic Leukemia; Diffuse Large B-Cell Lymphoma; Hematopoietic and Lymphoid Cell Neoplasm; Indolent Non-Hodgkin Lymphoma; Mantle Cell Lymphoma; Myelodysplastic Syndrome; Myeloproliferative Neoplasm; Prolymphocytic Leukemia; Recurrent Chronic Lymphocytic Leukemia; Recurrent Plasma Cell Myeloma; Refractory Chronic Lymphocytic Leukemia; Refractory Chronic Myelogenous Leukemia, BCR-ABL1 Positive; Refractory Hodgkin Lymphoma; Small Lymphocytic Lymphoma; T-Cell Chronic Lymphocytic Leukemia; Waldenstrom Macroglobulinemia
    Interventions
    Allogeneic Hematopoietic Stem Cell Transplantation; Cyclosporine; Fludarabine Phosphate; Mycophenolate Mofetil; Peripheral Blood Stem Cell Transplantation; Sirolimus; Total-Body Irradiation
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2010-11
    Completion
    2017-06-30
    Enrolment
    174

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAcute Lymphoblastic Leukemia; Acute Myeloid Leukemia; Aggressive Non-Hodgkin Lymphoma; Chronic Lymphocytic Leukemia +15 more
    InterventionAllogeneic Hematopoietic Stem Cell Transplantation; Cyclosporine; Fludarabine Phosphate; Mycophenolate Mofetil +3 more
    PhasePhase 3
    Registry statusCompleted

  • Temsirolimus With or Without Cetuximab in Patients With Recurrent and/or Metastatic Head and Neck Cancer Who Did Not Respond to Previous Therapy

    NCT01256385 · start 2010-11

    Registered record
    Registry ID
    NCT01256385
    Conditions
    Recurrent Hypopharyngeal Squamous Cell Carcinoma; Recurrent Laryngeal Squamous Cell Carcinoma; Recurrent Laryngeal Verrucous Carcinoma; Recurrent Lip and Oral Cavity Squamous Cell Carcinoma; Recurrent Metastatic Squamous Cell Carcinoma in the Neck With Occult Primary; Recurrent Nasal Cavity and Paranasal Sinus Squamous Cell Carcinoma; Recurrent Nasopharyngeal Keratinizing Squamous Cell Carcinoma; Recurrent Oral Cavity Verrucous Carcinoma; Recurrent Oropharyngeal Squamous Cell Carcinoma; Recurrent Salivary Gland Carcinoma; Salivary Gland Squamous Cell Carcinoma; Squamous Cell Carcinoma Metastatic in the Neck With Occult Primary; Stage IV Hypopharyngeal Squamous Cell Carcinoma; Stage IV Nasopharyngeal Keratinizing Squamous Cell Carcinoma; Stage IVA Laryngeal Squamous Cell Carcinoma; Stage IVA Laryngeal Verrucous Carcinoma; Stage IVA Lip and Oral Cavity Squamous Cell Carcinoma; Stage IVA Major Salivary Gland Carcinoma; Stage IVA Nasal Cavity and Paranasal Sinus Squamous Cell Carcinoma; St
    Interventions
    Cetuximab; Laboratory Biomarker Analysis; Temsirolimus
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2010-11
    Completion
    2013-12
    Enrolment
    86

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionRecurrent Hypopharyngeal Squamous Cell Carcinoma; Recurrent Laryngeal Squamous Cell Carcinoma; Recurrent Laryngeal Verrucous Carcinoma; Recurrent Lip and Oral Cavity Squamous Cell Carcinoma +16 more
    InterventionCetuximab; Laboratory Biomarker Analysis; Temsirolimus
    PhasePhase 2
    Registry statusCompleted

  • Reparixin in Pancreatic Islet Transplantation

    NCT01220856 · start 2010-07-28

    Registered record
    Registry ID
    NCT01220856
    Conditions
    Pancreatic Islet Transplantation in Type 1 Diabetes Mellitus
    Interventions
    Reparixin
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2010-07-28
    Completion
    2013-04-30
    Enrolment
    9

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionPancreatic Islet Transplantation in Type 1 Diabetes Mellitus
    InterventionReparixin
    PhasePhase 2
    Registry statusCompleted